Table 1_Dapagliflozin associates with heart rate variability decline in T2DM patients on G

Ying Wang's dataset contains results from a prospective observational study on 45 patients with type 2 diabetes mellitus (T2DM). The data likely includes heart rate variability (HRV) parameters measured before and after 12 weeks of GLP-1 receptor agonist therapy, comparing patients with and without baseline dapagliflozin use. The dataset was last updated on 2026-05-11.

Use Cases

• Analyzing changes in heart rate variability (HRV) parameters like SDNN and RMSSD based on treatment group.
• Investigating the association between baseline dapagliflozin use and attenuation of GLP-1 RA-related HRV decline.
• Validating statistical methods such as inverse probability of treatment weighting (IPTW) and multivariable linear regression on clinical outcome data.
• Comparing within-group and between-group differences in cardiac autonomic function metrics over a 12-week period.

Strengths

• Data originates from a prospective observational study design with a defined cohort of 45 patients.
• Analysis includes multiple statistical adjustment methods (ANCOVA, IPTW, multivariable regression) for robustness.
• HRV parameters were assessed using 24-hour ambulatory electrocardiography, a standard clinical method.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study's small sample size of 45 patients is noted by the authors as requiring confirmation in larger studies.

Provenance

Source

Ying Wang via figshare

Collection Method

Prospective observational study with data collected via 24-hour ambulatory electrocardiography.

Time Range

Study involved a 12-week treatment period.

Freshness

Last updated 2026-05-11 04:25:38; freshness should be verified.